NCCN 2023 Conference Highlights

Molecular/genetic characterization has taken on greater importance in the classification of adult gliomas and in diagnostic and treatment decision-making. “These tumors are now grouped and predicated more on molecular features rather than histopathologic criteria,” said L. Burt Nabors, MD, in a presentation during the 2023 National Comprehensive Cancer Network Annual Conference. Read More ›

In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and identified key factors for selecting frontline and subsequent therapies, including immunoglobulin heavy chain variable gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›

Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib, sunitinib, and other tyrosine kinase inhibitors. Read More ›